ACA
AUTL

Avoro Capital Advisors’s Autolus Therapeutics AUTL Stock Holding History

Avoro Capital Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,910,642
Closed -$15.4M – 31
2025
Q1 		$15.4M Hold
9,910,642
– – 0.24% 31
2024
Q4 		$23.3M Sell
9,910,642
-2,435,036
-20% -$8.23M 0.33% 34
2024
Q3 		$44.8M Hold
12,345,678
– – 0.65% 27
2024
Q2 		$43M Hold
12,345,678
– – 0.57% 30
2024
Q1 		$78.8M Buy
+12,345,678
New +$77M 0.92% 25

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Avoro Capital Advisors's AUTL Position: Q2 2025 in Review

Avoro Capital Advisors sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 9,910,642 shares — an estimated $15.4M sold.

Avoro Capital Advisors first reported a position in AUTL in Q1 2024 and held it in 5 quarters. The position peaked at $78.8M in Q1 2024. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

  • Avoro Capital Advisors reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avoro Capital Advisors sold 9,910,642 Autolus Therapeutics shares in Q2 2025, an estimated $15.4M.
  • Avoro Capital Advisors first reported a position in Autolus Therapeutics in Q1 2024 and held it in 5 quarters.
  • Avoro Capital Advisors's Autolus Therapeutics position peaked at $78.8M in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Avoro Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.